Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Susann Wittig"'
Autor:
Kristin Dawczynski, Nadine Pfaffendorf, Eberhard Kauf, Felix Zintl, Susann Wittig, Daniel Steinbach
Publikováno v:
Pediatric Blood & Cancer. 50:24-28
Insulin-like growth factor (IGF) system as regulator for cellular proliferation is of particular interest in search for new prognostic approaches in cancer treatment.We analyzed the mRNA expression profile of IGF-I, -II, and IGFBP-2, -3 in 50 childre
Autor:
Silke Furchtbar, Kristin Dawczynski, Daniel Steinbach, Susann Wittig, Felix Zintl, Jana Friedrich, Axel Sauerbrey, B. Gruhn
Publikováno v:
Leukemia & Lymphoma. 46:1357-1363
Drug resistance can be caused by ATP-binding-cassette (ABC)-transporters which function as outward pumps for chemotherapeutic drugs. The aim of the present study was to analyze the association between eight ABC-transporters (BCRP, MDR1, SMRP, MRP1, M
Autor:
Susanne Viehmann, Susann Wittig, Bernd Gruhn, Angelika Mueller, Ralf Haefer, Felix Zintl, Daniel Steinbach, Gunnar Cario, Axel Sauerbrey
Publikováno v:
Blood. 102:4493-4498
The family of multidrug resistance-associated proteins (MRPs) belongs to the superfamily of adenosine triphosphate-binding-cassette (ABC) transporters, which have the ability to function as outward pumps for chemotherapeutic drugs and therefore might
Publikováno v:
Leukemia & Lymphoma. 43:875-879
In this study, 86 children (58 initial ALL and 28 children with relapsed disease) were investigated for lung resistance protein (LRP) and multidrug resistance related protein (MRPI)-mRNA expression by semiquantitative RT-PCR. The majority of investig
Autor:
Felix Zintl, Masanori Onda, Astrid Voigt, Daniel Steinbach, Kristin Dawczynski, Alexander Schramm, Angelika Eggert, Susann Wittig, Andreas Rump, Ira Pastan, Nadine Pfaffendorf, Bernd Gruhn
Background: Monitoring of minimal residual disease (MRD) has become a strong diagnostic tool in acute lymphoblastic leukemia. It is used for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3663f1ab02be1a0808052fddec208fd8
https://www.ncbi.nlm.nih.gov/pubmed/16638849
https://www.ncbi.nlm.nih.gov/pubmed/16638849
Autor:
Felix Zintl, Alexander Schramm, Angelika Eggert, Daniel Steinbach, Susann Wittig, Bernd Gruhn
Publikováno v:
Blood. 104:2008-2008
Monitoring of minimal residual disease (MRD) has become one of the strongest diagnostic tools in the treatment of acute leukemia. MRD data after induction therapy can be used for risk group stratification. Long-term monitoring of MRD may allow predic